ARTBIO
ARTBIO is a clinical-stage radiopharmaceutical company focused on advancing cancer care through the development of alpha radioligand therapies (ARTs). Founded in 2021, the company aims to create targeted cancer treatments by combining alpha-emitting isotopes with ligands that target specific tumor markers. ARTBIO's approach integrates a deep understanding of cancer biology with the infrastructure needed for designing, manufacturing, and distributing these therapies. The company's lead program, AB001, is being developed for prostate cancer treatment. ARTBIO is also innovating with its Pb-212 isolation technology, *AlphaDirect TM*, to enhance the production and distribution of alpha-emitting isotopes. With significant funding from partners like F-Prime Capital and Omega Funds, ARTBIO is building a comprehensive ecosystem to ensure effective delivery of its therapies to eligible patients, emphasizing a patient-centric approach in its mission to improve cancer treatment outcomes.
Work at ARTBIO in HR or recruiting? Claim this page
Headcount trend
ARTBIO went from 14 employees in Oct 2024 to 32 in Sep 2026. Apr to Sep 2026: 5 people joined, 2 left.
Funding rounds
| Date | Round | Money raised | No. | Investors |
|---|---|---|---|---|
| Dec 2023 | Series A | $90M | 2 | |
| Jun 2023 | Seed | $23M | 1 |
Org structure
Headcount by department
Peer reviews
Worked with someone at ARTBIO?
Anonymous peer reviews on OffTheRecord
Similar companies
Hiring now
ARTBIO FAQ
How many employees does ARTBIO have?
ARTBIO has about 32 employees, up 14.3% over the 3 months to Sep 2026.
What is ARTBIO's revenue per employee?
ARTBIO makes about $56K in revenue per employee, based on $1.78M annual revenue and 32 employees.
How much funding has ARTBIO raised?
ARTBIO has raised $113M in total funding; its latest round was Series A in Dec 2023.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.